Tjian Robert 4
4 · Nurix Therapeutics, Inc. · Filed Jul 29, 2020
Insider Transaction Report
Form 4
Tjian Robert
Director
Transactions
- Conversion
Common Stock
2020-07-28+50,000→ 124,999 total(indirect: By Trust) - Conversion
Series B Preferred Stock
2020-07-28−50,000→ 0 total(indirect: By Trust)→ Common Stock (50,000 underlying) - Conversion
Common Stock
2020-07-28+41,666→ 74,999 total(indirect: By Trust) - Conversion
Series A-2 Preferred Stock
2020-07-28−41,666→ 0 total(indirect: By Trust)→ Common Stock (41,666 underlying)
Footnotes (2)
- [F1]The Series A-2 and Series B Preferred Stock automatically converted into shares of the Issuer's common stock on a one-for-one basis immediately upon the closing of the Issuer's initial public offering and had no expiration date.
- [F2]The Reporting Person is a trustee of the Tjian Belcher Revocable Trust. The Reporting Person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of such securities for purposes of Section 16 or for any other purposes.